FDA Finalizes Human Factors Submission Guidance: Key Takeaways

The FDA has finalized its guidance document, Content of Human Factors Information in Medical Device Marketing Submissions. The final guidance document supersedes the draft guidance issued in 2022 and provides medical device manufacturers with a clearer risk-based framework for determining what human factors (HF) information should be included in regulatory device submissions.

Overall, the final guidance aims to improve consistency, reduce unnecessary documentation, and help FDA reviewers efficiently assess whether use-related risks have been adequately addressed.

Key takeways

1. FDA emphasizes risk-based approach

Rather than expecting the same level of HF documentation for every device, FDA now clearly frames submission expectations around:

• Use-related risks
• Presence of critical tasks
• User interface modifications
• Potential impact of design changes on safe and effective use

The final guidance repeatedly emphasizes that the level of human factors information included in a submission should be proportional to the device’s use-related risk profile.

2. Critical tasks remain the central decision point

The final guidance reinforces that critical tasks continue to be the primary focus of FDA’s human factors review.

FDA defines a critical task a user task which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, where harm is defined to include compromised medical care.

For novel devices, critical tasks help determine which user interactions require human factors validation testing. For modified devices, the guidance places additional emphasis on evaluating whether design changes affect existing critical tasks or introduce new ones. Even seemingly minor user interface changes may warrant additional human factors evidence if they impact how users perform critical tasks.

Ultimately, the guidance reinforces a principle that has long existed within FDA’s human factors framework: the level of human factors evidence should be driven by the tasks that matter most to safe and effective device use. The final guidance reinforces that critical tasks remain one of the primary drivers for determining required HF documentation.

3. Human factors validation is not required for every submission

One of the most important clarifications in the final guidance is that FDA does not expect every submission to include a human factors validation study.

Instead, manufacturers are encouraged to evaluate the device’s user interface, critical tasks, use-related risks, and any design modifications to determine the appropriate level of human factors evidence. Depending on the nature of the device or change, this may range from a rationale explaining why additional human factors data are not required, to targeted human factors activities, or a full human factors validation study.

This risk-based approach helps focus testing efforts where they are most needed, while reducing the likelihood of unnecessary human factors studies for lower-risk devices or modifications that do not meaningfully impact user interactions.

4. Device modifications require a human factors assesment

A major focus of the final guidance is helping manufacturers determine whether modifications to an existing device warrant additional human factors evidence.

Rather than automatically requiring new testing for every design change, FDA expects manufacturers to assess whether the modification could affect the safety and effectiveness of user-device interactions. This includes evaluating whether the change impacts:

• The user interface
• How users perform critical tasks
• Existing use-related hazards
• Previously implemented risk control measures

Importantly, even seemingly minor modifications may warrant additional human factors justification if they could influence user behavior or task performance. Conversely, manufacturers may be able to leverage existing human factors data when they can demonstrate that a change does not meaningfully affect use-related risk.

This provides a more structured framework for determining when additional human factors activities are necessary and when existing evidence may remain sufficient. uses, and use environments.

5. Traceability is key

Throughout the guidance, FDA emphasizes the importance of demonstrating a logical connection between:

• Use-related hazards
• Critical tasks
• Risk controls
• Human factors evaluations
• Residual risk conclusions

In practice, this places additional importance on maintaining a robust Use-Related Risk Analysis (URRA) and ensuring clear traceability throughout the HF engineering process.

6. Clarity on human factors submission expectations

One of the most valuable aspects of the final guidance is the expanded set of examples illustrating the types of human factors information FDA may expect for different device and submission scenarios.

The guidance includes example pathways for:

• Novel devices
• Modified devices
• Devices with and without critical tasks
• Changes that may or may not impact use-related risk
• Situations where existing human factors evidence may be leveraged

These examples provide manufacturers with a more transparent framework for determining the appropriate level of human factors documentation to include in a submission.

7. FDA Moves Beyond the “Highest Priority Devices” List

For many regulatory and human factors teams, this added clarity should improve predictability when planning human factors activities and preparing marketing submissions, particularly when assessing whether additional testing or justification may be required.

The final guidance shifts the focus away from whether a device appears on FDA’s draft List of Highest Priority Devices for Human Factors Review and toward a more structured, risk-based assessment of the device itself.

Rather than relying on predefined device categories, manufacturers are encouraged to determine the appropriate level of human factors evidence based on the device’s user interface, critical tasks, use-related risks, and any design modifications.

What does this mean for medical device manufacturers?

The final guidance provides manufacturers with greater clarity on the type and amount of human factors information FDA may expect in a marketing submission.

Rather than relying on broad device categories, medical device manufacturers should focus on demonstrating how use-related risks were identified and mitigated, how critical tasks were determined, and why the submitted human factors evidence is sufficient to claim the device is reasonably safe and effective.

For many organizations, this will place greater emphasis on maintaining a robust use-related risk analysis (URRA), clearly defining critical tasks, and ensuring traceability throughout the human factors engineering process.

Ultimately, the final guidance should improve predictability for both manufacturers and FDA reviewers by providing a more structured framework for determining appropriate human factors submission content.